ClinicalTrials.gg
CompletedNCT00815659EFFORTUpdated Aug 31, 2011Results posted

Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome

A Phase 4 interventional study of rosuvastatin in Metabolic Syndrome, sponsored by AstraZeneca. Completed at 6 sites in Turkey. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2011-08-31.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 54 studies in Metabolic Syndrome with a site in Turkey — 14 open to participants now, 16 under way, none of them phase 3. Metabolic Syndrome · Turkey.

Enrollment
8th of 20
97 · median 76
Started
2008
the only one that year
Phase 4
4 of 54
none open now
Registered
4th of 54
by date

Among the 54 studies in Metabolic Syndrome with a site in Turkey, this one is the 8th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2008, is one of 4 in phase 4, and was the 4th registered.

Metabolic Syndrome

2,118 studies on the registry are indexed under Metabolic Syndrome; 348 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

14 of the 54 studies in Metabolic Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Metabolic Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.

03

Conditions studied

  • Metabolic Syndrome

Browse trials for

Keywords

  • plasma lipid profile
  • metabolic syndrome
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • metabolic syndrome (according to National Cholesterol Education Program (NCEP) Adenosine triphosphate (ATP) Ill criteria)
  • LDL-Cholesterol > 130mg/dl
  • HDL-Cholesterol \< 40mg/dl in males and \<50mg/dl in females
  • Triglycerides \< 400 mg/dl

Exclusion criteria

Exclusion Criteria:

  • With a concomitant coronary disease
  • Currently under statin therapy or previously treated with statins within the last 6 months
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Rosuvastatin

    medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.

    Drug: rosuvastatin

Interventions

  • medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.

    Also known as: CRESTOR

06

What researchers measure

Primary outcomes

  1. Basal HDL-cholesterol Level

    HDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)

    Time frame: Baseline

  2. HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment

    HDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  3. Basal LDL-cholesterol Level

    LDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)

    Time frame: Baseline

  4. LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment

    LDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  5. Basal Total Cholesterol Level

    Baseline

    Time frame: Total cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)

  6. Total Cholesterol Level After 3 Months of Rosuvastatin Treatment

    Total cholesterol after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  7. Basal Triglyceride Level

    Triglyceride levels before (mean of visit 1 - screening and Visit 2 - enrollment)

    Time frame: Baseline

  8. Triglyceride Level After 3 Months of Rosuvastatin Treatment

    Triglycerides after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  9. Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment

    Number of patients who reached target level of LDL-cholesterol after 3 months of rosuvastatin treatment. Target level: LDL-cholesterol: \<100 mg/dL; HDL-cholesterol: For males \>40 mg/dL, for females \>50 mg/dL; non-HDL-cholesterol: \<130 mg/dL

    Time frame: 3 months (from enrollment to last visit)

  10. Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment

    Number of patients who reached target level of HDL-cholesterol after 3 months of rosuvastatin treatment

    Time frame: 3 months (from enrollment to last visit)

  11. Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment

    Number of patients who reached target level of non-HDL-cholesterol after 3 months of rosuvastatin treatment

    Time frame: 3 months (from enrollment to last visit)

Secondary outcomes

  1. Basal Interleukin 1 (IL-1) Level

    IL-1 levels before (Visit 2-enrollment)

    Time frame: Baseline

  2. Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment

    IL-1 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  3. Basal Interleukin 6 (IL-6) Level

    IL-6 levels before (Visit 2-enrollment)

    Time frame: Baseline

  4. Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment

    IL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  5. Basal Interleukin 8 (IL-8) Level

    IL-8 levels before (Visit 2-enrollment)

    Time frame: Baseline

  6. Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment

    IL-8 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  7. Basal Interleukin 10 (IL-10) Level

    IL-10 levels before (Visit 2-enrollment)

    Time frame: Baseline

  8. Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment

    IL-10 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  9. Basal Tumor Necrosis Factor (TNF) Level

    TNF levels before (Visit 2-enrollment)

    Time frame: Baseline

  10. Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment

    TNF levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  11. Basal High Sensitivity C-reactive Protein (Hs-CRP) Level

    hs-CRP levels before (Visit 2-enrollment)

    Time frame: Baseline

  12. High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment

    hs-CRP levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  13. Basal LDL-3 Level

    LDL subfractions are light (LDL1 and 2), intermediate (LDL3) and small dense LDL (LDL 4, 5, 6 and 7). Small dense LDL (sdLDL)-cholesterol that expresses greater atherogenicity than large buoyant LDL. Large LDL particles are the least likely to cause plaque formation, because LDL particles have to be approximately 25 nm in diameter or smaller to penetrate the artery walls. High sdLDL and decreased large HDL fraction are more common in patients with coronary heart disease than in controls

    Time frame: Baseline

  14. LDL-3 Level After 3 Months of Rosuvastatin Treatment

    LDL-3 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  15. Basal LDL-4 Level

    LDL-4 levels before (Visit 2-enrollment)

    Time frame: Baseline

  16. LDL-4 Level After 3 Months of Rosuvastatin Treatment

    LDL-4 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  17. Basal LDL-5 Level

    LDL-5 levels before (Visit 2-enrollment)

    Time frame: Baseline

  18. LDL-5 Level After 3 Months of Rosuvastatin Treatment

    LDL-5 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  19. Basal LDL-6 Level

    LDL-6 levels before (Visit 2-enrollment)

    Time frame: Baseline

  20. LDL-6 Level After 3 Months of Rosuvastatin Treatment

    LDL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  21. Basal LDL-7 Level

    LDL-7 levels before (Visit 2-enrollment)

    Time frame: Baseline

  22. LDL-7 Level After 3 Months of Rosuvastatin Treatment

    LDL-7 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  23. Basal Large HDL Subfraction Level

    Large HDL subfraction levels before (Visit 2-enrollment)

    Time frame: Baseline

  24. Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment

    Large HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  25. Basal Intermediate HDL Subfraction Level

    Intermediate HDL subfraction levels before (Visit 2-enrollment)

    Time frame: Baseline

  26. Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment

    Intermediate HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  27. Basal Small HDL Subfraction Level

    Small HDL subfraction levels before (Visit 2-enrollment)

    Time frame: Baseline

  28. Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment

    Small HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

    Time frame: 3 months (from enrollment to last visit)

  29. Number of Patients With Adverse Events

    Number of patients with any adverse events in 3 months of rosuvastatin treatment

    Time frame: 3 months (from enrollment to last visit)

07

Results

Posted Jul 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneCrestor
Started97
Completed74
Not completed23
Withdrew: Adverse event9
Withdrew: Withdrawal by subject9
Withdrew: Lost to follow-up4
Withdrew: Protocol violation1

Outcome measures

PrimaryBasal HDL-cholesterol Level

HDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/dL
Basal HDL-cholesterol Level
mg/dLCrestor
Basal HDL-cholesterol Level39.5 ± 6.5
PrimaryHDL-cholesterol Level After 3 Months of Rosuvastatin Treatment

HDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/dL
HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
mg/dLCrestor
HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment43.4 ± 9.8
PrimaryBasal LDL-cholesterol Level

LDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/dL
Basal LDL-cholesterol Level
mg/dLCrestor
Basal LDL-cholesterol Level165.5 ± 32.0
PrimaryLDL-cholesterol Level After 3 Months of Rosuvastatin Treatment

LDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/dL
LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment
mg/dLCrestor
LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment98.3 ± 44.8
PrimaryBasal Total Cholesterol Level

Baseline

Time frame:
Total cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)
Reported as:
Mean · mg/dL
Basal Total Cholesterol Level
mg/dLCrestor
Basal Total Cholesterol Level236.5 ± 38.2
PrimaryTotal Cholesterol Level After 3 Months of Rosuvastatin Treatment

Total cholesterol after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/dL
Total Cholesterol Level After 3 Months of Rosuvastatin Treatment
mg/dLCrestor
Total Cholesterol Level After 3 Months of Rosuvastatin Treatment166.2 ± 47.7
PrimaryBasal Triglyceride Level

Triglyceride levels before (mean of visit 1 - screening and Visit 2 - enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/dL
Basal Triglyceride Level
mg/dLCrestor
Basal Triglyceride Level195.1 ± 65.3
PrimaryTriglyceride Level After 3 Months of Rosuvastatin Treatment

Triglycerides after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/dL
Triglyceride Level After 3 Months of Rosuvastatin Treatment
mg/dLCrestor
Triglyceride Level After 3 Months of Rosuvastatin Treatment153.1 ± 76.8
PrimaryNumber of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment

Number of patients who reached target level of LDL-cholesterol after 3 months of rosuvastatin treatment. Target level: LDL-cholesterol: \<100 mg/dL; HDL-cholesterol: For males \>40 mg/dL, for females \>50 mg/dL; non-HDL-cholesterol: \<130 mg/dL

Time frame:
3 months (from enrollment to last visit)
Reported as:
Number · Participants
Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment
ParticipantsCrestor
Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment48
PrimaryNumber of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment

Number of patients who reached target level of HDL-cholesterol after 3 months of rosuvastatin treatment

Time frame:
3 months (from enrollment to last visit)
Reported as:
Number · Participants
Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment
ParticipantsCrestor
Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment39
PrimaryNumber of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment

Number of patients who reached target level of non-HDL-cholesterol after 3 months of rosuvastatin treatment

Time frame:
3 months (from enrollment to last visit)
Reported as:
Number · Participants
Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment
ParticipantsCrestor
Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment51
SecondaryBasal Interleukin 1 (IL-1) Level

IL-1 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · pg/mL
Basal Interleukin 1 (IL-1) Level
pg/mLCrestor
Basal Interleukin 1 (IL-1) Level4.1 ± 2.3
SecondaryInterleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment

IL-1 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · pg/mL
Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment
pg/mLCrestor
Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment4.1 ± 2.2
SecondaryBasal Interleukin 6 (IL-6) Level

IL-6 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · pg/mL
Basal Interleukin 6 (IL-6) Level
pg/mLCrestor
Basal Interleukin 6 (IL-6) Level2.6 ± 2.1
SecondaryInterleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment

IL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · pg/mL
Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment
pg/mLCrestor
Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment2.8 ± 2.8
SecondaryBasal Interleukin 8 (IL-8) Level

IL-8 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · pg/mL
Basal Interleukin 8 (IL-8) Level
pg/mLCrestor
Basal Interleukin 8 (IL-8) Level10.7 ± 5.1
SecondaryInterleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment

IL-8 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · pg/mL
Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment
pg/mLCrestor
Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment12.7 ± 13.3
SecondaryBasal Interleukin 10 (IL-10) Level

IL-10 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · pg/mL
Basal Interleukin 10 (IL-10) Level
pg/mLCrestor
Basal Interleukin 10 (IL-10) Level4.2 ± 2.1
SecondaryInterleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment

IL-10 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · pg/mL
Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment
pg/mLCrestor
Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment4.8 ± 3.9
SecondaryBasal Tumor Necrosis Factor (TNF) Level

TNF levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · pg/mL
Basal Tumor Necrosis Factor (TNF) Level
pg/mLCrestor
Basal Tumor Necrosis Factor (TNF) Level10.8 ± 5.3
SecondaryTumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment

TNF levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · pg/mL
Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment
pg/mLCrestor
Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment12.9 ± 9.2
SecondaryBasal High Sensitivity C-reactive Protein (Hs-CRP) Level

hs-CRP levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal High Sensitivity C-reactive Protein (Hs-CRP) Level
mg/mLCrestor
Basal High Sensitivity C-reactive Protein (Hs-CRP) Level8.2 ± 7.3
SecondaryHigh Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment

hs-CRP levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment6.7 ± 5.6
SecondaryBasal LDL-3 Level

LDL subfractions are light (LDL1 and 2), intermediate (LDL3) and small dense LDL (LDL 4, 5, 6 and 7). Small dense LDL (sdLDL)-cholesterol that expresses greater atherogenicity than large buoyant LDL. Large LDL particles are the least likely to cause plaque formation, because LDL particles have to be approximately 25 nm in diameter or smaller to penetrate the artery walls. High sdLDL and decreased large HDL fraction are more common in patients with coronary heart disease than in controls

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal LDL-3 Level
mg/mLCrestor
Basal LDL-3 Level15.5 ± 9.5
SecondaryLDL-3 Level After 3 Months of Rosuvastatin Treatment

LDL-3 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
LDL-3 Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
LDL-3 Level After 3 Months of Rosuvastatin Treatment8.8 ± 7.9
SecondaryBasal LDL-4 Level

LDL-4 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal LDL-4 Level
mg/mLCrestor
Basal LDL-4 Level7.9 ± 9.6
SecondaryLDL-4 Level After 3 Months of Rosuvastatin Treatment

LDL-4 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
LDL-4 Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
LDL-4 Level After 3 Months of Rosuvastatin Treatment3.5 ± 4.8
SecondaryBasal LDL-5 Level

LDL-5 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal LDL-5 Level
mg/mLCrestor
Basal LDL-5 Level2.7 ± 7.1
SecondaryLDL-5 Level After 3 Months of Rosuvastatin Treatment

LDL-5 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
LDL-5 Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
LDL-5 Level After 3 Months of Rosuvastatin Treatment1.3 ± 3.5
SecondaryBasal LDL-6 Level

LDL-6 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal LDL-6 Level
mg/mLCrestor
Basal LDL-6 Level0.5 ± 2.6
SecondaryLDL-6 Level After 3 Months of Rosuvastatin Treatment

LDL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
LDL-6 Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
LDL-6 Level After 3 Months of Rosuvastatin Treatment0.3 ± 1.5
SecondaryBasal LDL-7 Level

LDL-7 levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal LDL-7 Level
mg/mLCrestor
Basal LDL-7 Level0.5 ± 3.0
SecondaryLDL-7 Level After 3 Months of Rosuvastatin Treatment

LDL-7 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
LDL-7 Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
LDL-7 Level After 3 Months of Rosuvastatin Treatment0.8 ± 5.3
SecondaryBasal Large HDL Subfraction Level

Large HDL subfraction levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal Large HDL Subfraction Level
mg/mLCrestor
Basal Large HDL Subfraction Level15.0 ± 6.4
SecondaryLarge HDL Subfraction Level After 3 Months of Rosuvastatin Treatment

Large HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment17.6 ± 7.6
SecondaryBasal Intermediate HDL Subfraction Level

Intermediate HDL subfraction levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal Intermediate HDL Subfraction Level
mg/mLCrestor
Basal Intermediate HDL Subfraction Level18.9 ± 5.7
SecondaryIntermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment

Intermediate HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment19.9 ± 6.1
SecondaryBasal Small HDL Subfraction Level

Small HDL subfraction levels before (Visit 2-enrollment)

Time frame:
Baseline
Reported as:
Mean · mg/mL
Basal Small HDL Subfraction Level
mg/mLCrestor
Basal Small HDL Subfraction Level6.2 ± 4.2
SecondarySmall HDL Subfraction Level After 3 Months of Rosuvastatin Treatment

Small HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)

Time frame:
3 months (from enrollment to last visit)
Reported as:
Mean · mg/mL
Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment
mg/mLCrestor
Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment6.6 ± 4.6
SecondaryNumber of Patients With Adverse Events

Number of patients with any adverse events in 3 months of rosuvastatin treatment

Time frame:
3 months (from enrollment to last visit)
Reported as:
Number · Participants
Number of Patients With Adverse Events
ParticipantsCrestor
Number of Patients With Adverse Events24

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crestor—0/97 (0%)29/97 (29.9%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCrestor
Pruritus-Allergy-RashSkin and subcutaneous tissue disorders5/97
HeadacheSkin and subcutaneous tissue disorders4/97
MyalgiaMusculoskeletal and connective tissue disorders2/97
CK IncreasedInvestigations2/97
DysuriaInfections and infestations2/97
Upper Respiratory Tract InfectionInfections and infestations2/97
Liver Function Tests AbnormalInfections and infestations2/97
NauseaGastrointestinal disorders1/97
AllergyGastrointestinal disorders1/97
DermatoidSkin and subcutaneous tissue disorders1/97

Baseline characteristics

Age Continuous
Age Continuous(Years)Crestor
Mean50.9 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Crestor
Female57
Male40
08

Study locations

6 sites
  • Research site
    Ankara, Besevler, Turkey
  • Research site
    Kayseri, Erciyes, Turkey
  • Research site
    Istanbul, Haseki, Turkey
  • Research site
    Kocaeli, Umuttepe, Turkey
  • Research Site
    Izmir, Turkey
  • Research Site
    Trabzon, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2008
First posted
Dec 30, 2008
Start
Dec 2008
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jul 4, 2011
Last update
Aug 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00815659
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 30, 2008
Start date
Dec 2008
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jul 4, 2011
Last update
Aug 31, 2011

Study contacts

Dilek Ural, MD, Prof
principal investigator · Kocaeli University Faculty of Medicine Cardiology Dept

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion